Sort
64,565 grants matching “drug discovery”
Identification of CYP5122A1 inhibitors as chemical probes for Leishmania biology
$648,204Zhuo Michael Wang · University Of Kansas Lawrence · R01 · FY2019 · AI
Defining the targets of broad intervention antimalarial agents
$648,140Elizabeth A Winzeler · University Of California, San Diego · R01 · FY2013 · AI
Clinical Core
$648,129Linda J Van Eldik · University Of Kentucky · P30 · FY2012 · AG
Phase 2 Bridging Pre-transplant Inflammatory Dampening for Primary Immune Regulatory Disorders (BRIDGE Trial)
$648,109Joseph H Oved · Sloan-Kettering Inst Can Research · R01 · FY2023 · FD
Accurate protein folding software to predict ligand-induced conformational changes in G protein-coupled receptors
$648,084Steven Joseph Darnell · Dnastar, Inc. · R44 · FY2017 · GM
Qualification of Prognostic and Diagnostic Biomarkers of Knee Osteoarthritis
$648,020Virginia B. Kraus · Duke University · R01 · FY2018 · AR
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
$648,000Joan H Schiller · Ut Southwestern Medical Center · U10 · FY2014 · CA
Developing Cyclopeptide Nef Inhibitors to Facilitate HIV-1 Eradication
$647,861Xiaofei Jia · Florida State University · R01 · FY2025 · AI
Molecular mechanisms of bacterial homologs of neurotransmitter:sodium symporters
$647,818Jonathan A Javitch · Columbia University Health Sciences · R01 · FY2010 · DA
Molecular Mechanism of RhoA-mediated Ca2+-sensitization in Vascular Smooth Muscle
$647,800Avril V. Somlyo · University Of Virginia · R01 · FY2017 · GM
Molecular Mechanism of RhoA-mediated Ca2+-sensitization in Vascular Smooth Muscle
$647,800Avril V. Somlyo · University Of Virginia · R01 · FY2014 · GM
Molecular Mechanism of RhoA-mediated Ca2+-sensitization in Vascular Smooth Muscle
$647,800Avril V. Somlyo · University Of Virginia · R01 · FY2015 · GM
Molecular Mechanism of RhoA-mediated Ca2+-sensitization in Vascular Smooth Muscle
$647,800Avril V. Somlyo · University Of Virginia · R01 · FY2016 · GM
Evaluating the therapeutic potential of hypoxia mimetics in inflammatory demyelinating disease
$647,782D. Richard Milner · San Diego Biomedical Research Institute · R01 · FY2024 · NS
Synthetic mRNA-mediated reversible immunocontraception
$647,780Philip J Santangelo · Emory University · R33 · FY2022 · HD
Deciphering fundamental biological processes involving protein-nucleic acid interactions at the molecular level
$647,751Maria Schumacher · Duke University · R35 · FY2024 · GM
Deciphering fundamental biological processes involving protein-nucleic acid interactions at the molecular level
$647,751Maria Schumacher · Duke University · R35 · FY2025 · GM
Epi-seq: Multiplexed ChIP-seq for personalized medicine and drug discovery
$647,683Mary Anne Jelinek · Active Motif, Inc. · R44 · FY2020 · HG
Transforming growth factor β family signaling pathways in ovarian and uterine biology
$647,661Martin M Matzuk · Baylor College Of Medicine · R01 · FY2025 · HD
Mechanisms of Neuropeptides Action in Diabetes
$647,619Aristidis Veves · Beth Israel Deaconess Medical Center · R01 · FY2011 · DK
ALCOHOL DEPENDENCE IN AFRICAN AMERICANS: A CASE-CONTROL GENETIC STUDY
$647,614Richard A Grucza · Washington University · R01 · FY2011 · AA
Maternal mediators of fetal growth restriction linked to prenatal alcohol exposure
$647,586Christina Chambers · University Of California, San Diego · R01 · FY2023 · AA
Mycobacterium tuberculosis antigen diversity
$647,571Joel D. Ernst · New York University School Of Medicine · R01 · FY2012 · AI
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief
$647,556Vsevolod Katritch · University Of Southern California · UH3 · FY2022 · NS
Phase 2 Bridging Pre-transplant Inflammatory Dampening for Primary Immune Regulatory Disorders (BRIDGE Trial)
$647,533Joseph H Oved · Sloan-Kettering Inst Can Research · R01 · FY2024 · FD